Drug intelligence / Profile preview

XEN1701

Development stage: Preclinical
Lead developer: Xenon Pharmaceuticals
Modality: Small Molecules
Administration: Oral (inferred As Typical For Small Molecule Drugs; No Explicit Data Found)

Overview

XEN1701 is a novel small molecule inhibitor targeting the Nav1.7 voltage-gated sodium channel. It is being developed by Xenon Pharmaceuticals for the treatment of pain. The drug acts by inhibiting Nav1.7 sodium channels, which are involved in the transmission of pain signals, making it a potential analgesic agent. XEN1701 represents a new molecular entity and is currently in preclinical development stages for pain indications.

Other names: XEN-1701XEN1701XEN 1701

Targets

SCN9A (Sodium channel protein type 9 subunit alpha)

Beyond the preview

Go deeper on XEN1701.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on XEN1701.

Explore the full profile